Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

Provencio, M; Terrasa, J; Garrido, P; Campelo, RG; Aparisi, F; Diz, P; Aguiar, D; Garcia-Giron, C; Hidalgo, J; Aguado, C; Gonzalez, JG; Esteban, E; Gomez-Aldavari, L; Moran, T; Juan, O; Chara, LE; Marti, JL; Castro, RL; Ortega, AL; Moreno, EM; Coves, J; Pena, AMS; Bosch-Barrera, J; Gastaldo, AS; Nunez, NF; del Barco, E; Cobo, M; Isla, D; Majem, M; Navarro, F; Calvo, V – 2021